Xinhua Pharma's Calcium Deficiency Drug Gets Generic Status in China

MT NewswiresNov 5 05:58 ET

Shandong Xinhua's Generic Drug Receives Key Approval

TipRanksNov 5 04:40 ET

Shandong Xinhua Pharmaceutical Unit Passes Generic Drug Consistency Evaluation for Antibiotic

MT NewswiresNov 5 04:19 ET

shandong xinhua pharmaceutical (000756.SZ): Xinda Pharmaceuticals' Cefuroxime Axetil dispersible tablets passed the generic drug consistency evaluation.

On November 4th, Geruihui announced that Shandong Xinhua Pharmaceutical (000756.SZ) recently, Shandong Xinhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as 'Xinda Pharmaceutical'), received the National Medical Products Administration's approval and issuance of the cephalosporin cefuroxime axetil dispersible tablets (referred to as 'this product') Supplementary Application Approval Notice for pharmaceuticals, approving this product to pass the generic drug quality and efficacy consistency evaluation. Cefuroxime axetil belongs to the second generation cephalosporin antibiotic, is the oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, is tolerant to most β-lactamases, and can be widely effective against gram-positive.

Gelonghui FinanceNov 4 03:54 ET

shandong xinhua pharmaceutical (00719.HK): Wholly-owned subsidiary's pharmaceutical products passed generic drug consistency evaluation.

Gelonghui November 4th | shandong xinhua pharmaceutical (00719.HK) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceuticals Co., Ltd. ("Xinda Pharmaceuticals"), recently received the National Medical Products Administration's approved and issued Ceftibuten Dispersible Tablets (referred to as "this product") "Drug Supplementary Application Approval Notice", approving this product through generic drug quality and efficacy consistency evaluation.

Gelonghui FinanceNov 4 03:42 ET

Express News | Shandong Xinhua Pharmaceutical - Drugs of Unit Passing Generics Consistency Evaluation

ReutersNov 4 03:41 ET